Overview

This trial is active, not recruiting.

Condition cervical degenerative disc disease
Treatments prestige® lp cervical disc, atlantis anterior cervical plate
Phase phase 3
Sponsor Medtronic Spinal and Biologics
Start date January 2005
End date January 2008
Trial size 280 participants
Trial identifier NCT00667459, PRESTIGE® LP Protocol, #P03-03

Summary

The purpose of this clinical trial is to evaluate the safety and effectiveness of the PRESTIGE® LP Cervical Disc as a method of treating patients with symptoms of cervical degenerative disc disease at a single level from C3-C4 to C6-C7.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
PRESTIGE® LP Cervical Disc
prestige® lp cervical disc PRESTIGE® LP
The PRESTIGE® LP Cervical Disc is inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
(Active Comparator)
The study uses a group of patients who received a ACDF fusion treatment in a previous IDE trial (G010188)
atlantis anterior cervical plate ATLANTIS plate
Anterior cervical discectomy and fusion with ATLANTIS plate from control group from IDE study G010188.

Primary Outcomes

Measure
Overall Success
time frame: 24 months

Secondary Outcomes

Measure
Pain/Disability Success
time frame: 24 months
Overall Neurological Status
time frame: 24 months
Disc Height
time frame: 24 months
General Health Status
time frame: 24 months
Neck Pain and Arm Pain
time frame: 24 months
Gait Assessment
time frame: 24 months
Surgery and Hospitalization Information
time frame: At the time of discharge
Additional Surgical Procedures/Interventions
time frame: 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Has cervical degenerative disc disease as defined as: intractable radiculopathy and/or myelopathy with at least one of the following items producing symptomatic nerve root and/or spinal cord compression that is documented by patient history: a) herniated disc; b) osteophyte formation - One level requiring surgical treatment - C3-C4 disc to C6-C7 disc level involvement - Unresponsive to non-operative treatment for six weeks or presence of progressive symptoms or signs of cord compression - No previous surgical procedures at the involved level or any planned surgical procedure at the involved or adjacent level. - Preop Neck Disability index score ≥ 30 - Preop Neck Pain score of ≥ 20 based on the Preop Neck & Arm Pain Questionnaire - Not pregnant at time of surgery - Willing and able to comply with study plan and able to understand and sign patient informed consent Exclusion Criteria: - Any other cervical spinal condition requiring surgical treatment at the involved level - Documented or diagnosed cervical instability defined by radiographs showing 1. Sagittal plane translation > 3.5mm or 2. Sagittal plane angulation > 20 degrees. - More than one cervical level requiring surgery - A fused level adjacent to the level to be treated - Severe pathology of the facet joint of involved bodies - Previous surgery at the involved level - Previously diagnosed osteopenia or osteomalacia - Any of the following that may be associated with an osteoporosis diagnosis (if "Yes" to any of these, a DEXA Scan will be required to determine eligibility) 1. Postmenopausal non-Black female over 60 years of age and weighs less than 140 pounds 2. Postmenopausal female that has sustained a non-traumatic hip, spine, or wrist fracture 3. Male over the age of 70 4. Male over the age of 60 that has sustained a non-traumatic hip or spine fracture. If the level of Bone Mineral Density is a T score of -3.5 or lower or a T score of -2.5 or lower with the vertebral crush fracture, then the patient is excluded. - Presence of spinal metastases - Overt or active bacterial infection, either local or systemic - Severe insulin dependent diabetes - Chronic or acute renal failure or history of renal disease - Temperature > 101º F oral at surgery - Documented allergy to stainless steel, titanium or a titanium alloy - Mentally incompetent - Is a prisoner - Is pregnant - Is an alcohol and/or drug abuser - Has received drugs which may interfere with bone metabolism within 2 weeks prior to the planned surgery date (steroids, methotrexate), excluding routine preop anti-inflammatories) - A history of endocrine or metabolic disorder known to affect osteogenesis - A condition that requires postop medications that interfere with the stability of the implant (steroids). This does not include low dose aspirin therapy. - Received treatment with an investigational therapy within 28 days prior to surgery or planned for 16 weeks following implantation.

Additional Information

Official title A Prospective, Multicenter, Controlled Clinical Trial of an Artificial Cervical Disc LP at a Single Level for Symptomatic Cervical Disc Disease
Description This pivotal clinical trial is being conducted to compare treatment data of the investigational implant device,the PRESTIGE® LP Cervical Disc, with a control patient group receiving a plate. The PRESTIGE® LP Cervical Disc device will be implanted using an anterior surgical approach. Data from control patients receiving anterior cervical discectomy and fusion with an ATLANTIS Anterior Cervical Plate from the initial Artificial Cervical Disc study (IDE # G010188)will be compared as both treatment groups receive single-level surgical treatment from C3-C4 to C6-C7 for symptomatic cervical degenerative disc disease.
Trial information was received from ClinicalTrials.gov and was last updated in February 2013.
Information provided to ClinicalTrials.gov by Medtronic Spinal and Biologics.